Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Triastek Announces Research Collaboration and Platform Technology License Agreement with BioNTech
Jul 23, 2024•about 2 years ago
Contract Type
partnership
NanjingManufacturingBiotechnologyPharmaceutical
Description
Triastek Inc. has entered into a research collaboration and platform technology license agreement with BioNTech SE to develop RNA therapeutics for oral delivery based on 3D printing technology. The collaboration aims to provide groundbreaking therapies to address unmet medical needs in an easy to administer oral formulation.
Company Information
Company
Triastek
Location
Nanjing, Jiangsu, China
About
Founded in 2015, Triastek, Inc. is the global leader in the 3D printing of pharmaceuticals and is pioneering the implementation of digital pharmaceutical solutions. Triastek’s novel and proprietary 3D printing technology platform, encompasses dosage form design, digital pharmaceutical product development, and intelligent manufacturing.
Triastek has the largest product pipeline based on 3D printing technology in the world, with the company’s 1st and 2nd products (T19 and T20) having received IND clearance from the U.S. Food and Drug Administration (FDA). The company also holds the highest number of patent applications related to 3D printing of pharmaceuticals, providing the most comprehensive patent coverage of any 3D printing pharmaceutical company in the world.
NanjingManufacturingBiotechnologyPharmaceutical